Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01275 (
glucagon
)
26,492
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Glucagon
is found to interact with dimyristoyl glycerophosphocholine both above and below the phase transition temperature of the lipid. Above the phase transition temperature the interaction is manifested by an increase in the rate of vesicle aggregation and by an increased permeability of unilamellar vesicles to Eu3+ and to
Fe(CN)3
-6. However, no stable lipoprotein complex can be detected by gel filtration. Below the phase transition
glucagon
can form stable complexes with dimyristoyl glycerophosphocholine vesicles but cannot rapidly rearrange these vesicles to disk-shaped particles until the phase transition temperature is approached. The energy of activation for the dissociation of
glucagon
from the disk-shaped lipoprotein particle is 29 kcal/mol at temperatures above 36 degrees C but increases markedly at lower temperatures, as the region of the lipid phase transition is approached. This increase in energy of activation at lower temperatures is most probably due to the larger amount of energy required to rearrange gel-state lipid in the transition state and provides an explanation for the unusual kinetic stability of the
glucagon
-dimyristoyl glycerophosphocholine lipoprotein complex only at temperatures below the phase transition of the lipid.
...
PMID:Studies on the effect of the lipid phase transition on the interaction of glucagon with dimyristoyl glycerophosphocholine. 73 67